Quetiapine: A review of its use in the management of bipolar depression

CNS Drugs

Volumn 26, Issue 5, 2012, Pages 435-460

  Sanford, Mark ^a   Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Evaluations; Bipolar I disorders; Bipolar II disorders; Depression; Pharmacokinetics; Pharmacology; Quetiapine

Indexed keywords

CARBAMAZEPINE; CLARITHROMYCIN; DOPAMINE; DOPAMINE RECEPTOR; ERYTHROMYCIN; FLUCONAZOLE; FLUOXETINE; GLUCOSE; ITRACONAZOLE; KETOCONAZOLE; LAMOTRIGINE; LITHIUM; NEFAZODONE; NORADRENALIN; OLANZAPINE; PLACEBO; PROLACTIN; QUETIAPINE; RISPERIDONE; THIORIDAZINE; VALPROATE SEMISODIUM; ZIPRASIDONE;

AKATHISIA; ANEMIA; ANTIDEPRESSANT ACTIVITY; ANXIETY DISORDER; AREA UNDER THE CURVE; BIPOLAR DEPRESSION; BIPOLAR I DISORDER; BIPOLAR II DISORDER; BRAIN REGION; CONSTIPATION; CONTROLLED DRUG RELEASE; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOPAMINE RELEASE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; EMBASE; EVENING DOSAGE; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; INCREASED APPETITE; INSOMNIA; LEUKOPENIA; LIVER TOXICITY; MAJOR DEPRESSION; MANIA; MAXIMUM PLASMA CONCENTRATION; MEDLINE; MENTAL PATIENT; METHODOLOGY; MONOTHERAPY; MORNING DOSAGE; NAUSEA; NEUROMODULATION; NEUROTRANSMISSION; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PANCYTOPENIA; PHARMACODYNAMICS; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; QUALITY OF LIFE; RATING SCALE; RECOMMENDED DRUG DOSE; RECURRENT DISEASE; REMISSION; REVIEW; RHINOPHARYNGITIS; RISK REDUCTION; SCHIZOPHRENIA; SOCIAL INTERACTION; SOMNOLENCE; STEADY STATE; SYNAPTIC TRANSMISSION; SYSTEMATIC REVIEW; TREATMENT RESPONSE; URINE RETENTION; XEROSTOMIA;

ADMINISTRATION, ORAL; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DELAYED-ACTION PREPARATIONS; DIBENZOTHIAZEPINES; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; RECEPTORS, DOPAMINE D2; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS;

EID: 84859940784     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11203840-000000000-00000     Document Type: Review

References (70)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 2000
2. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005 Jun;62: 593-602 (Pubitemid 40973434)
3. Kupfer DJ. The increasing medical burden in bipolar disorder. JAMA 2005 May 25;293 (20): 2528-30 (Pubitemid 40705735)
4. Ösby U, Brandt L, Correia N, et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 2001 Sep;58 (9): 844-50 (Pubitemid 32979302)
5. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002 Jun;59 (6): 530-7 (Pubitemid 34602935)
6. Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003 Mar;60 (3): 261-9 (Pubitemid 36307437)
7. Pharmacotherapy of psychosis and mania. In: Brunton LL, editor. Goodman &Gilman's The pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill, 2006;461-500
8. Nierenberg AA. An analysis of the efficacy of treatments for bipolar depression. J Clin Psychiatry 2008;69 Suppl. 5: 4-8
9. Cruz N, Sanchez-Moreno J, Torres F, et al. Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis. Int J Neuropsychopharmacol 2010 Feb;13 (1): 5-15
10. Van Lieshout RJ, MacQueen GM. Efficacy and acceptability of mood stabilisers in the treatment of acute bipolar depression: systematic review. Br J Psychiatry 2010 Apr;196 (4): 266-73
11. AstraZeneca. Seroquel (quetiapine): summary of product characteristics [online]. Available from URL: http://www. medicine.org.uk/emc/medicine/2295 [Accessed 2010 Jun 24]
12. AstraZeneca. Seroquel (quetiapine fumarate) tablets: prescribing information [online]. Available from URL: http://www.accessdata.fda.gov/ drugsatfda-docs/label/2009/020639 s045s046lbl.pdf [Accessed 2010 Jun 24]
13. AstraZeneca. Seroquel XR-(quetiapine fumarate) extendedrelease tablets: prescribing information [online]. Available from URL: http://www.accessdata.fda. gov/drugsatfda-docs/label/2009/022047s011s016s017s019s022lbl.pdf [Accessed 2010 Jun 24]
14. AstraZenica PharmaceuticalsUKLtd. Seroquel XL 50 mg, 200mg, 300mg, 400mg prolonged-release tablets: summary of product characteristics [online]. Available from URL: http://www.medicines.org.uk/emc/document.aspx?document id=21175&docType=SPC [Accessed 2010 Jul 5]
15. Kapur S, Seeman P. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 2001 Mar;158 (3): 360-9 (Pubitemid 32205190)
16. Yatham LN, Goldstein JM, Vieta E, et al. Atypical antipsychotics in bipolar depression: potential mechanisms of action. J Clin Psychiatry 2005;66 Suppl. 5: 40-8 (Pubitemid 40934073)
17. McIntyre RS, Soczynska JK, Woldeyohannes HO, et al. A preclinical and clinical rationale for quetiapine in mood syndromes. Expert Opin Pharmacother 2007 Jun;8 (9): 1211-9 (Pubitemid 47034411)
18. Keating GM, Robinson DM. Quetiapine: a review of its use in the treatment of bipolar depression. Drugs 2007;67 (7): 1077-95 (Pubitemid 46744479)
19. Jensen NH, Rodriguiz RM, Caron MG, et al. Ndesalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 2008 Sep;33 (10): 2303-12
20. Nyberg S, Takano A, Jucaite A, et al. PET-measured occupancy of the norepinephrene transporter by extended release quetiapine fumarate (quetiapine XR) in brains of healthy subjects [abstract no. P.1.e.019]. Eur Neuropsychopharmacol 2008;18 Suppl. 4: s270
21. Datto C, Berggren L, Patel JB, et al. Self-reported sedation profile of immediate-release quetiapine fumarate compared with extended-release quetiapine fumarate during dose initiation: a randomized, double-blind, crossover study in healthy adult subjects. Clin Ther 2009 Mar;31 (3): 492-502
22. Gefvert O, Lundberg T, Wieselgren IM, et al. D2 and 5HT2A receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. Eur Neuropsychopharmacol 2001 Apr;11 (2): 105-10 (Pubitemid 32335553)
23. Mamo DC, Uchida H, Vitcu I, et al. Quetiapine extendedrelease versus immediate-release formulation: a positron emission tomography study. J Clin Psychiatry 2008 Jan;69 (1): 81-6 (Pubitemid 351282000)
24. Newcomer JW, Ratner RE, Eriksson JW, et al. A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone. J Clin Psychiatry 2009 Apr;70 (4): 487-99
25. Montgomery SA. The under-recognized role of dopamine in the treatment of major depressive disorder. Int Clin Psychopharmacol 2008 Mar;23 (2): 63-9 (Pubitemid 351317278)
26. Sparshatt A, Jones S, Taylor D. Quetiapine: dose-response relationship in schizophrenia. CNS Drugs 2008;22 (1): 49-68;discussion 69-72 (Pubitemid 350243366)
27. De Vane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet 2001;40 (7): 509-22
28. Figueroa C, Brecher M, Hamer-Maansson JE, et al. Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release. Prog Neuropsychopharmacol Biol Psychiatry 2009 Mar 17;33 (2): 199-204
29. Aichhorn W, Marksteiner J, Walch T, et al. Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentrations. Int Clin Psychopharmacol 2006 Mar;21 (2): 81-5 (Pubitemid 43740314)
30. Potkin SG, Thyrum PT, Alva G, et al. The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine. J Clin Psychopharmacol 2002 Apr;22 (2): 121-30 (Pubitemid 34289386)
31. Potkin SG, Thyrum PT, Alva G, et al. Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine. J Clin Psychopharmacol 2002 Apr;22 (2): 174-82 (Pubitemid 34289392)
32. Winter HR, DeVane CL, Figueroa C, et al. Open-label steady-state pharmacokinetic drug interaction study on coadministered quetiapine fumarate and divalproex sodium in patients with schizophrenia, schizoaffective disorder, or bipolar disorder. Hum Psychopharmacol 2007 Oct;22 (7): 469-76 (Pubitemid 47611302)
33. Potkin SG, Thyrum PT, Bera R, et al. Open-label study of the effect of combination quetiapine/lithium therapy on lithium pharmacokinetics and tolerability. Clin Ther 2002 Nov;24 (11): 1809-23 (Pubitemid 35440952)
34. Wang J-S, Zhu H-J, Markowitz JS, et al. Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl) 2006 Sep;187 (4): 415-23 (Pubitemid 44200513)
35. Calabrese JR, Keck Jr PE, MacFadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. The BOLDER Study Group. Am J Psychiatry 2005 Jul;162 (7): 1351-60 (Pubitemid 40905587)
36. Thase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). BOLDER II Study Group. J Clin Psychopharmacol 2006 Dec;26 (6): 600-9 (Pubitemid 44772737)
37. Suppes T, Datto C, Minkwitz M, et al. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. J Affect Disord 2010 Feb;121 (1-2): 106-15
38. Young AH, McElroy SL, Bauer M, et al. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). EMBOLDEN I Investigators. J Clin Psychiatry 2010 Feb;71 (2): 150-62
39. McElroy SL, Weisler RH, Chang W, et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). EMBOLDEN II Investigators. J Clin Psychiatry 2010 Feb;71 (2): 163-74
40. Young AH, McElroy SL, Olausson B, et al. A randomised, placebo-controlled 52-week trial of continued quetiapine treatment in recently depressed patients with bipolar I and bipolar II disorder.World J Biol Psychiatry. Epub 2012Mar 12
41. Weisler RH, Nolen WA, Neijber A, et al. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (trial 144: a randomized controlled study). J Clin Psychiatry 2011 Nov;72 (11): 1452-64
42. Hamilton M. A rating scale for depression. J Neurol Neurosurg 1960;23 (1): 56-62
43. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978;133 (5): 429-35 (Pubitemid 9006756)
44. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Brit J Psychiat 1979 Apr;134 (4): 382-9 (Pubitemid 9136500)
45. Duru G, Fantino B. The clinical relevance of changes in the Montgomery-Asberg Depression Rating Scale using the minimum clinically important difference approach. Curr Med Res Opin 2008;24 (5): 1329-35 (Pubitemid 351741564)
46. Solvay Pharmaceuticals, Inc. Lithibid (lithium carbonate slow-release) 300 mg tablets: prescribing information [online]: Available from URL: http://www.accessdata.fda. gov/drugsatfda-docs/label/2002/18027s40s46s49lbl.pdf [Accessed 2010 Oct 21]
47. GlaxoSmithKline. Paxil (paroxetine hydrochloride) tablets and oral suspension: prescribing information [online]. Available from URL: http://us.gsk.com/products/assets/us-paxil.pdf [Accessed 2010 Jun 25]
48. Guy W, editor. ECDEU assessment manual for psychopharmacology. Rockville (MD): US Department of Health, Education and Welfare, 1976
49. Cookson J, Keck Jr PE, Ketter TA, et al. Number needed to treat and time to response/remission for quetiapine monotherapy efficacy in acute bipolar depression: evidence from a large, randomized, placebo-controlled study. Int Clin Psychopharmacol 2007 Mar;22 (2): 93-100
50. Sheehan DV. The anxiety disease. New York: Scribner, 1983
51. Hirschfeld RMA, Weisler RH, Raines SR, et al. Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis froma randomized, doubleblind, placebo-controlled study. BOLDER Study Group. J Clin Psychiatry 2006 Mar;67 (3): 355-62
52. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32: 50-5
53. Endicott J, Rajagopalan K, Minkwitz M, et al. A randomized, double-blind, placebo-controlled study of quetiapine in the treatment of bipolar I and II depression: improvements in quality of life. Int Clin Psychopharmacol 2007;22 (1): 29-37 (Pubitemid 44950765)
54. Suppes T, Hirschfeld RM, Vieta E, et al. Quetiapine for the treatment of bipolar II depression: analysis of data from two randomized, double-blind, placebo-controlled studies. World J Biol Psychiatry 2008;9 (3): 198-211
55. Vieta E, Calabrese JR, Goikolea JM, et al. Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2007 Jun;9 (4): 413-25 (Pubitemid 46865372)
56. Posner K, Oquendo MA, Gould M, et al. Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am J Psychiatry 2007 Jul;164 (7): 1035-43 (Pubitemid 47121392)
57. National Institute for Health and Clinical Excellence. Bipolar disorder: the management of bipolar disorder in adults, children and adolescents, in primary and secondary care (NICE clinical guideline 38) [online]. Available from URL: http://www.nice.org.uk/nicemedia/pdf/CG38niceguide line.pdf [Accessed 2010 Jun 23]
58. The Royal Australian and New Zealand College of Psychiatrists. Bipolar disorder: Australian treatment guide for consumers and carers [online]. Available from URL: http://www.ranzcp.org?images/stories/ranzcp-attachments/ Resour ces/Publications/CPG/Australian-Versions/AUS-Bipolar-disorder.pdf [Accessed 2010 Jul 15]
59. Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009 May;11 (3): 225-55
60. Hirschfeld RMA. Guideline watch: practice guideline for the treatment of patients with bipolar disorder. 2nd ed. American Psychiatric Association [online]. Available from URL: http://www.psychiatryonline.com/pracGuide/Prac ticePDFs/Bipolar.watch.pdf [Accessed 2010 Jul 15]
61. Thase ME. Quetiapine monotherapy for bipolar depression. Neuropsychiatr Dis Treat 2008 Feb;4 (1): 11-21
62. Baldessarini RJ. Treatment research in bipolar disorder: issues and recommendations. CNS Drugs 2002;16 (11): 721-9 (Pubitemid 35252721)
63. Tondo L, Baldessarini RJ. Long-term lithium treatment in the prevention of suicidal behaviour in bipolar disorder patients. Epidemiol Psichiatr Soc 2009 Jul;18 (3): 179-83
64. DelBello MP, Chang K, Welge JA, et al. A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder. Bipolar Disord 2009 Aug;11 (5): 483-93
65. Grant BF, Stinson FS, Dawson DA, et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders. Arch Gen Psychiatry 2004 Aug;61 (8): 807-16
66. Mehta DK, editor. British national formulary. 2006 ed. London: BMJ Publishing Group Ltd., 2006
67. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics. CNS Drugs 2007;21 (11): 911-36
68. Woodward TC, Tafesse E, Quon P, et al. Cost effectiveness of adjunctive quetiapine fumarate extended-release tablets with mood stabilizers in the maintenance treatment of bipolar I disorder. Pharmacoeconomics 2010;28 (9): 751-64
69. Meier G, von Maltzahn R, Parkinson BT. Cost-effectiveness of quetiapine extended-release versus paroxetine and lithium in acute bipolar depression [abstract no. PMH48]. 12th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research;2009 Oct 24-27;Paris
70. Meier G, Edwards SJ, von Maltzahn R. Cost-effectiveness of quetiapine extended release versus other atypical antipsychotics in acute bipolar depression [abstract no. PMH49]. 12th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research;2009 Oct 24-27;Paris